Over the past decade, a succession of new GvHD treatments targeting different components of the immune response have been ...
AstraZeneca has set itself the goal of reaching $80 billion in annual revenue by 2030, up from $58.7 billion in 2025. Its oncology business continues to grow, but AstraZeneca is also looking to newer ...